Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer

被引:150
作者
Das, P
Skibber, JM
Rodriguez-Bigas, MA
Feig, BW
Chang, GJ
Hoff, PM
Eng, C
Wolff, RA
JanJan, NA
Delclos, ME
Krishnan, S
Levy, LB
Ellis, LM
Crane, CH
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, U97, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2006年 / 29卷 / 03期
关键词
rectal cancer; predictive factors; local recurrence; metastasis; survival; Cox model;
D O I
10.1097/01.coc.0000214930.78200.4a
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objectives: To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer. Methods: Between 1989 and 2001, 470 patients with rectal cancer were treated with preoperative (89%) or postoperative (11%) chemoradiation and mesorectal excision. Median radiation dose was 45 Gy; 97% received concurrent infusional 5-fluorouracil, and 65% received adjuvant chemotherapy. Median follow-up interval was 5.7 years. Results: The 5-year rates of freedom from LR, freedom from DM, and OS were 90%, 79%, and 80%, respectively. On univariate analysis, significant predictors of LR were female sex, clinical T stage, pathologic T and N stages, and positive radial margin. Significant univariate predictors of DM were circumferential extent of tumor, tumor immobility, lymphovascular invasion, perineural involvement, and pathologic T and N stages. Significant univariate predictors of lower OS were age, circumferential extent of tumor, shorter distance from anal verge, tumor size, tumor immobility, anal canal involvement, lymphovascular invasion, perineural involvement, positive radial margin, and pathologic T and N stages. On Cox multivariate analysis, female sex and pathologic T and N stages independently predicted for LR; pathologic T and N stages independently predicted for DM; and age, circumferential extent of tumor, positive radial margin, and pathologic T and N stages independently predicted for lower OS. Conclusions: Pathologic T and N stages significantly predicted for all 3 end points (LR, DM and OS) on multivariate analysis. Investigations of more aggressive adjuvant chemotherapy appear warranted for pathologic stage T3/T4 or N1/2 rectal cancer.
引用
收藏
页码:219 / 224
页数:6
相关论文
共 19 条
[1]
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]
[Anonymous], 1985, N ENGL J MED, V312, P1465
[3]
Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: A population-based analysis [J].
Baxter, NN ;
Morris, AM ;
Rothenberger, DA ;
Tepper, JE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02) :426-431
[4]
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[5]
Bosset JF, 2005, J CLIN ONCOL, V23, p247S
[6]
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[7]
Fleming ID., 1997, AJCC CANC STAGING HD
[8]
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis [J].
Gunderson, LL ;
Sargent, DJ ;
Tepper, JE ;
Wolmark, N ;
O'Connell, MJ ;
Begovic, M ;
Allmer, C ;
Colangelo, L ;
Smalley, SR ;
Haller, DG ;
Martenson, JA ;
Mayer, RJ ;
Rich, TA ;
Ajani, JA ;
MacDonald, JS ;
Willett, CG ;
Goldberg, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1785-1796
[9]
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[10]
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer [J].
Janjan, NA ;
Abbruzzese, J ;
Pazdur, R ;
Khoo, VS ;
Cleary, K ;
Dubrow, R ;
Ajani, J ;
Rich, TA ;
Goswitz, MS ;
Evetts, PA ;
Allen, PK ;
Lynch, PM ;
Skibber, JM .
RADIOTHERAPY AND ONCOLOGY, 1999, 51 (02) :153-160